Reviews/Alcohol and Health/Heavy alcohol causes cirrhosis
Liver Mortality · ALC-LM-01 · v1
Borderline: within 4 points of the Established/Likely boundary, so a re-grade could land either side.
The evidence here lines up strongly in one direction: among people who drink heavily, cirrhosis is far more common, and the pattern gets stronger the more they drink [22]. Genetic-based analysis adds support that alcohol itself, not just factors that travel with drinking, drives liver injury [21], though that analysis measured liver fat and scarring rather than cirrhosis itself. Six separate studies from different countries all treat alcohol-caused cirrhosis as a well-recognised condition [3][11][12][23], and none of them points the other way. The main caveats are that the single study measuring cirrhosis directly looks at people at one point in time rather than following them over the years [22], and that the cleanest causal review in the corpus could not be used because it is a narrative review [20]. The panel landed where it did because the signals converge, while acknowledging the most direct evidence has these structural limits.
A large population analysis of 17,007 US adults found heavy drinking conferred a 5.14-fold increased cirrhosis risk (95% CI 2.60-10.20, p < 0.001) and describes the alcohol-cirrhosis association as dose-dependent [22]. A multi-cohort analysis using Mendelian randomization supported a causal link between genetically predicted alcohol intake and liver fat and iron, with higher alcohol intake raising fibrosis risk (HR 1.47, 95% CI 1.42-1.52) [21]. Biomarker work in 60 patients with alcoholic liver cirrhosis documents the fibrosis substrate underlying the condition [12], and a prospective study states alcoholic liver disease is the leading cause of cirrhosis in Japan, with reduced drinking improving liver biochemistry [23]. A trial in biopsy-proven alcohol-related liver disease shows fibrosis progressing in 43% of placebo patients over 18 months, tracing the disease pathway [11]. No paper in the corpus contradicts the direction of effect. The contested point: The division is over how directly the corpus tests causation on the cirrhosis endpoint itself. The only paper whose outcome is cirrhosis [22] is cross-sectional and so cannot fix the temporal order, while the paper carrying causal (MR) inference [21] measures liver fat and fibrosis surrogates rather than cirrhosis, so no single primary study delivers a direct causal test on the stated outcome.
All 23 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Alcohol and Health, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The only included paper whose outcome is cirrhosis itself [22] is cross-sectional (NHANES), which cannot establish temporality and leaves residual confounding; the causal-inference paper [21] uses Mendelian randomization but its outcomes are liver fat/fibrosis/iron surrogates, not cirrhosis, so no single primary study delivers a causal test directly on the cirrhosis endpoint.
The treatment trials [3][11][12] recruit patients pre-labelled as alcoholic cirrhosis/ALD by clinicians; they evidence accepted etiology, not an independent demonstration of causation, so weighting them as causal support risks circular double-counting.
Where it remains uncertain. The single study measuring cirrhosis directly is cross-sectional [22] and the causal MR evidence targets fibrosis and liver-fat surrogates rather than cirrhosis [21], so the endpoint and the causal test are carried by different papers.
Aleatory
Not every heavy drinker develops cirrhosis; [20]'s risk factors (sex, age, obesity, diabetes, genetic variants) is excluded from synthesis, so the included corpus does not quantify who among heavy drinkers progresses.
Epistemic
The only cirrhosis-outcome paper [22] is cross-sectional, so the corpus holds no prospective data establishing that heavy drinking precedes cirrhosis onset.
Inferential
The causal (MR) inference in [21] targets liver fat, fibrosis and iron, not cirrhosis, so the inference to the cirrhosis endpoint relies on the fibrosis-to-cirrhosis continuum rather than direct measurement.
The load-bearing papers from a corpus of 23, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Documents the fibrotic substrate of alcoholic cirrhosis in a human cohort separating alcoholics with vs without cirrhosis
“In alcoholic liver cirrhosis, normal liver cells are replaced by scar tissue (fibrosis).”
Panel auditInternal validity: low · scope of inference: Biomarker differences among alcoholic patients stratified by cirrhosis stage.Key limitations: cross-sectional · no temporal/causal design · small control group
Prospective multi-cohort risk estimates on the fibrosis precursor to cirrhosis
“MR analysis further supported a causal link between genetically predicted alcohol intake and elevated liver iron and PDFF.”
Panel auditInternal validity: high · scope of inference: General-population alcohol consumers; endpoint is steatosis/fibrosis, with a J-shaped dose relationship.Key limitations: endpoint is fibrosis not cirrhosis · J-shaped association at low intake · observational cohorts despite MR support
Direct dose-dependent association on the cirrhosis outcome in a large population sample (n=17,007)
“This study confirms a dose-dependent alcohol-cirrhosis association”
Panel auditInternal validity: medium · scope of inference: US adults in NHANES; cirrhosis prevalence by drinking category.Key limitations: cross-sectional association · self-reported drinking · residual confounding possible
Results concern fibrosis reduction after cell therapy in already-cirrhotic abstinent patients, not whether alcohol caused the cirrhosis.
Panel auditInternal validity: medium · scope of inference: Abstinent patients with established alcoholic cirrhosis receiving BM-MSC.Key limitations: open-label · cirrhosis aetiology assumed not tested · treatment trial
4 of 23 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Strong dose-dependent effect on the cirrhosis outcome plus Mendelian-randomization causal support on the fibrosis precursor and near-unanimous corpus consistency carry a causal verdict, tempered to the band floor by reliance on a single cross-sectional study for the cirrhosis endpoint.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No prospective cohort to cirrhosis endpoint. The cirrhosis-outcome evidence [22] is cross-sectional, leaving temporality and residual confounding unresolved for the exact claim. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A long-term prospective cohort of baseline-non-cirrhotic heavy drinkers with quantified intake and biomarker-confirmed exposure, tracking incident biopsy- or elastography-confirmed cirrhosis.
Open question: Does heavy alcohol intake precede and predict incident cirrhosis when heavy drinkers are followed prospectively from a non-cirrhotic baseline? Why it is still open: The only cirrhosis-outcome paper in the corpus [22] measures exposure and outcome at a single time point and cannot establish temporal order.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19